How Calquence Targets Mantle Cell Lymphoma
Calquence (acalabrutinib) treats mantle cell lymphoma (MCL) by inhibiting Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell signaling pathway that drives cancer cell growth and survival.[1] In MCL, a type of non-Hodgkin lymphoma, malignant B-cells overexpress BTK, leading to uncontrolled proliferation. Calquence binds covalently to BTK, blocking signals from the B-cell receptor and other pathways like CXCR4 and CD19, which halts tumor cell expansion and induces cell death.[2][3]
Approved by the FDA in 2020 for relapsed or refractory MCL after at least one prior therapy, it shows response rates around 80% in trials, with median progression-free survival of 16-22 months depending on patient factors.[1][4]
How Calquence Differs from Other BTK Inhibitors Like Imbruvica
Calquence is more selective for BTK than ibrutinib (Imbruvica), avoiding off-target inhibition of kinases like EGFR and ITK, which reduces side effects such as atrial fibrillation (4-10% vs. 10-20% with ibrutinib) and bleeding.[2][5] This selectivity stems from its structure: a smaller molecule that forms a reversible bond initially before covalent attachment, improving tolerability.[3]
| Feature | Calquence | Imbruvica |
|---------|-----------|-----------|
| BTK Selectivity | High (minimal off-target) | Moderate |
| Common Doses for MCL | 100 mg twice daily | 560 mg once daily |
| Atrial Fibrillation Risk | Lower | Higher [5] |
What Happens in Clinical Trials for MCL
The pivotal ACE-LY-004 trial enrolled 124 relapsed/refractory MCL patients; 81% achieved objective response (58% complete), with median duration of response at 25 months.[1][4] Real-world data confirms similar efficacy in heavily pretreated cases, though responses shorten with multiple prior lines.[6]
Common Side Effects Patients Experience with Calquence in MCL
Most issues are manageable: diarrhea (30-40%), headache (20%), fatigue (20%), and infections (pneumonia in 10-15%). Serious risks include bleeding (9%), second cancers (9%), and cytopenias. BTK resistance emerges via mutations like C481S in 20-30% of cases after 1-2 years.[2][7] Monitoring includes regular blood counts and cardiac checks.
When Does Calquence's Patent Protection End for MCL Use
Calquence's core composition-of-matter patent (US 9,290,505) expires in 2031, with method-of-use patents for lymphomas extending to 2033-2037; pediatric exclusivity adds six months.[8] No generics expected before 2032, though challenges from companies like MSN and Dr. Reddy's are pending.[8]
Alternatives if Calquence Fails or Isn't Tolerated
- Other BTK inhibitors: Zanubrutinib (Brukinsa) or pirtobrutinib (LOXO-305) for resistance mutations.[5]
- CAR-T therapy: Brexucabtagene autoleucel (Tecartus) for refractory MCL, with 87% response but higher toxicity.[9]
- Combination regimens: Rituximab + chemotherapy, or bispecifics like glofitamab in trials.[6]
[1]: FDA Label - Calquence (acalabrutinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210259s017lbl.pdf
[2]: Nature Reviews Drug Discovery - BTK inhibitors in B-cell malignancies (2020).
[3]: Blood Journal - Mechanism of acalabrutinib (2018).
[4]: Lancet Oncology - ACE-LY-004 trial results (2021).
[5]: NEJM - Zanubrutinib vs. ibrutinib in MCL (2022).
[6]: ASCO Post - Real-world Calquence data (2023).
[7]: Cancer Discovery - BTK resistance mutations (2021).
[8]: DrugPatentWatch.com - Calquence patents. https://www.drugpatentwatch.com/p/tradename/CALQUENCE
[9]: FDA Approval - Tecartus for MCL (2020).